CORE
CO
nnecting
RE
positories
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Research partnership
About
About
About us
Our mission
Team
Blog
FAQs
Contact us
Community governance
Governance
Advisory Board
Board of supporters
Research network
Innovations
Our research
Labs
Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines
Authors
Allison
Antman
+35 more
Bielack
Blumberg
Crespi
Dalton
Dotzlaw
Elias
Gennuso
Honkakoski
Hughes
Hukkanen
Hustert
Keohan
Koyano
Kumar
Kumar
Leonard
Ling
Liu
Maglich
Masuyama
Obach
Oda
Pascussi
Pascussi
Pascussi
Potter
Schuetz
Sonneveld
Synold
Tabb
Wen
Wrighton
Xie
Yao
Zhuo
Publication date
1 January 2007
Publisher
'Wiley'
Doi
View
on
PubMed
Abstract
BACKGROUND. Approximately 30% to 40% of all patients with osteosarcomas ultimately experience recurrence. The study investigated the hypothesis that the resistance of osteosarcoma to chemotherapy may be related to the expression of a pregnane xenobiotic receptor (PXR) variant protein and its role as the major inducer of P450 3A4 in these tumors. METHODS. Polymerase chain reaction (PCR) and Western blot analysis were used to determine PXR mRNA and protein expression, respectively. Real-time PCR and CYP3A catalytic activity using 7-benzyl-trifluoromethyl coumarin (BFC) as the probe substrate were used to measure the induction of P450 3A4 or MDR1. siRNA transfections were performed for PXR and cytotoxicity determined by a colorimetric based assay or Annexin v-Fitc staining. RESULTS. Differences were observed in the molecular size of the PXR protein expressed in sarcoma cell lines when compared with the wildtype PXR expressed in normal liver, kidney, or small intestine. A polyclonal PXR antibody raised against the N-terminus of the wildtype PXR did not detect PXR expressed in these sarcoma cell lines. In the osteosarcoma cell lines, etoposide and doxorubicin were better inducers of P450 3A4 and MDR1 than rifampin. siRNA against PXR down-regulated P450 3A4 expression only in the osteosarcoma cell line. Cytotoxicity assays showed that the resistance of the osteosarcoma cell lines to etoposide correlated with PXR protein expression levels and activation of P450 3A4 and could be prevented by ketoconazole. CONCLUSION. The results suggest that PXR plays a critical role in the regulation of P450 3A4 expression in osteosarcoma and that its expression and activation in these tumors may influence the effect of chemotherapeutic agents on the induction of target genes implicated in drug resistance. Cancer 2007. © 2007 American Cancer Society.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/55931/1/22479_ftp.pd
Similar works
Full text
Available Versions
Deep Blue Documents
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:deepblue.lib.umich.edu:202...
Last time updated on 25/05/2012
Crossref
See this paper in CORE
Go to the repository landing page
Download from data provider
Last time updated on 01/04/2019